Company: SHPH
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001641172-25-009325
Chunk: 14

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Item 2
Chunk 14
---
. Our remediation efforts, including those noted
above, were completed and the related controls were in place for a sufficient period of time to conclude that these material weaknesses
were remediated as of March 31, 2025.

Changes
in Internal Control over Financial Reporting

There has been no change in the Company’s internal control over financial
reporting during the three months ended March 31, 2025 that has materially affected, or is reasonably likely to materially affect, the
Company’s internal control over financial reporting. Management will continue to monitor and evaluate the effectiveness of our internal
controls and procedures over financial reporting on an ongoing basis and is committed to taking further action and implementing additional
improvements as necessary.

31

PART II — OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Currently, there are no legal proceedings pending
or threatened against us. We are not presently party to any pending or other threatened legal proceedings or claims that we believe will
have a material adverse effect on our business, financial condition or operating results, although from time to time, we may become involved
in legal proceedings in the ordinary course of business.

ITEM 1A. RISK FACTORS

As a smaller reporting company, we are not required
to provide the information required by this item.

ITEM 2. UNREGISTERED SALES OF SECURITIES AND USE
OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Not Applicable.

ITEM 4. MINE SAFETY DISCLOSURES

Not Applicable.

ITEM 5. OTHER INFORMATION

During the quarter ended March 31, 2025, none of our
directors or executive officers adopted or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading
arrangement” (as each item is defined Item 408(a) of Regulation S-K).

Item 6.
Exhibits

The following exhibits are filed or furnished with
this report:

    Exhibit No.
     
    Description of Exhibit
  
    10.1
     
    Form of Pre-Funded Warrants (incorporated by reference to Exhibit 4.9 to the Registration Statement on Form S-1/A (File No. 333-284889) filed on March 5, 2025).
  
    10.2
     
    Amendment Agreement, dated February 26, 2025, between Shuttle Pharmaceuticals